NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- An FDA warning concerning HYCOAT, a recalled equine product sold under the Neogen Vet line, erased over 7% from Neogen Corporation (NASDAQ: NEOG) shares in a single trading session. NEOG shareholders who lost money on that move may have legal rights to seek recovery. Shareholders who suffered losses are encouraged to submit their NEOG loss information for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
According to reporting on the warning, FDA testing identified multiple fungal species in HYCOAT, a product marketed as sterile. Coverage cited nearly 100 affected horses and at least 20 horse deaths.
On July 30, 2026, during Neogen's fiscal fourth-quarter earnings call, CEO Mikhael Nassif told investors the Company had "resolved prior supply and quality challenges." The investigation concerns potential securities law violations and whether NEOG shareholders may be entitled to recover losses tied to the HYCOAT warning. Shareholders who have already sold their NEOG shares may still be eligible. There is no upfront cost to have a potential loss reviewed.
If you lost money on Neogen stock, request a free review of your shareholder rights or call Joseph E. Levi, Esq. at (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the NEOG Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Neogen made potentially false or misleading statements about the condition of its Animal Safety business and the resolution of supply and quality challenges affecting its Neogen Vet product line. When the FDA warning on the recalled HYCOAT equine product became public, NEOG shares fell 7.22%.
Q: When did Neogen allegedly mislead investors? A: The investigation concerns statements made before the FDA warning on HYCOAT that allegedly caused investors to buy NEOG securities at inflated prices.
Q: What do NEOG investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my NEOG shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NEOG and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. If you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
